HALT-IT trial, Tranexamic acid for the treatment of gastrointestinal haemorrhage: an international randomised, double blind placebo controlled trial
The HALT‐IT trial will determine the effect of early administration of TXA on mortality, morbidity (re‐bleeding, non‐fatal vascular events), blood transfusion, surgical intervention and health status in patients with acute gastrointestinal bleeding.
A pragmatic, randomised, double blind, placebo controlled trial among 8,000 patients with significant gastrointestinal bleeding.
Patients with significant GI bleeds in whom the use of tranexamic acid is neither indicated nor contraindicated
Professor Iain Roberts (LSHTM)
Dr Matt Reed (RIE)
Dr Nick Church
Dr James Dear
Dr Kallirroi Kefala
Julia Grahamslaw – local EMeRGE study lead
ED research nurses
1. Ambulatory Device, Rocket Pleural vent insertion
2. Standard Treatment, Aspiration +/- chest drain
Primary Outcome Measures
To assess whether use of an ambulatory device (Rocket Pleural Vent) and treatment strategy reduces hospital stay. Total length of stay in hospital up to 30 days post randomisation. Up to 30 days post randomisation.
RAMPP trial - Randomised Controlled Trial: Pleural vent (rocket) V standard care in Primary Spontaneous Pnuemothorax
Attitudes towards Research and Research Nurses among the clinical team in an Emergency Department (ED) and Acute Medical Unit (AMU)
Attitudes towards Research and Research Nurses
Traumatic Brain Injury (TBI) is the leading cause of death and disabilities amongst young people worldwide. Many sufferers develop chronic physical and mental health problems and are unable to work or re-engage socially after their injuries. There are therefore significant health and socioeconomic consequences.
A study examining the Prevalence and Risk of Anterior Pituitary Dysfunction following Traumatic Brain Injury